Abstract
Glutamate, first identified in 1866, is the primary excitatory neurotransmitter in the brain. While it is critically important in many highly regulated cortical functions such as learning and memory, glutamate can be much like the magic the Sorcerers Apprentice used in Goethes poem: when conjured under unregulated conditions glutamate can get quickly out of control and lead to deleterious consequences. Two broad types of glutamate receptors, the ionotropic and metabotropic, facilitate glutamatergic neurotransmission in the CNS and play key roles in regulating cognitive function. Excessive activation of these receptors leads to excitotoxicity, especially in brain regions that are developmentally and regionally vulnerable to this kind of injury. Dysregulation of glutamate signaling leads to neurodegeneration that plays a role in a number of neuropsychiatric diseases, prompting the development and utilization of novel strategies to balance the beneficial and deleterious potential of this important neurotransmitter. Inhibition of the enzyme glutamate carboxypeptidase II (GCPII) is one method of manipulating glutamate neurotransmission. Positive outcomes (decreased neuronal loss, improved cognition) have been demonstrated in preclinical models of ALS, stroke, and Multiple Sclerosis due to inhibition of GCPII, suggesting this method of glutamate regulation could serve as a therapeutic means for treating neurodegeneration and cognitive impairment.
Keywords: Glutamate, neurodegeneration, cognitive impairment, Glutamate Carboxypeptidase II (GCPII), NAAG peptidase, NAALADase, metabotropic glutamate receptor, ionotropic glutamate receptor, excitotoxicity, N-Acetyl-Apartyl Glutamate (NAAG), stroke, Alzheimer's, Disease, Alzheimer's Disease, Schizophrenia, Multiple Sclerosis
Current Medicinal Chemistry
Title: Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Volume: 19 Issue: 9
Author(s): K. A. Rahn, B. S. Slusher and A. I. Kaplin
Affiliation:
Keywords: Glutamate, neurodegeneration, cognitive impairment, Glutamate Carboxypeptidase II (GCPII), NAAG peptidase, NAALADase, metabotropic glutamate receptor, ionotropic glutamate receptor, excitotoxicity, N-Acetyl-Apartyl Glutamate (NAAG), stroke, Alzheimer's, Disease, Alzheimer's Disease, Schizophrenia, Multiple Sclerosis
Abstract: Glutamate, first identified in 1866, is the primary excitatory neurotransmitter in the brain. While it is critically important in many highly regulated cortical functions such as learning and memory, glutamate can be much like the magic the Sorcerers Apprentice used in Goethes poem: when conjured under unregulated conditions glutamate can get quickly out of control and lead to deleterious consequences. Two broad types of glutamate receptors, the ionotropic and metabotropic, facilitate glutamatergic neurotransmission in the CNS and play key roles in regulating cognitive function. Excessive activation of these receptors leads to excitotoxicity, especially in brain regions that are developmentally and regionally vulnerable to this kind of injury. Dysregulation of glutamate signaling leads to neurodegeneration that plays a role in a number of neuropsychiatric diseases, prompting the development and utilization of novel strategies to balance the beneficial and deleterious potential of this important neurotransmitter. Inhibition of the enzyme glutamate carboxypeptidase II (GCPII) is one method of manipulating glutamate neurotransmission. Positive outcomes (decreased neuronal loss, improved cognition) have been demonstrated in preclinical models of ALS, stroke, and Multiple Sclerosis due to inhibition of GCPII, suggesting this method of glutamate regulation could serve as a therapeutic means for treating neurodegeneration and cognitive impairment.
Export Options
About this article
Cite this article as:
A. Rahn K., S. Slusher B. and I. Kaplin A., Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition, Current Medicinal Chemistry 2012; 19 (9) . https://dx.doi.org/10.2174/092986712799462649
DOI https://dx.doi.org/10.2174/092986712799462649 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ADAM8/MS2/CD156, an Emerging Drug Target in the Treatment of Inflammatory and Invasive Pathologies
Current Pharmaceutical Design Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets Potential Prophylactic and Therapeutic Vaccines for HSV Infections
Current Pharmaceutical Design Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
Current Drug Targets Chronic HIV-1 Tat and HIV Reduce Rbfox3/NeuN: Evidence for Sex- Related Effects
Current HIV Research Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Recent Advances in the Development of Anti-Infective Prophylactic and/or Therapeutic Agents Based on Toll-Like Receptor (TLRs)
Recent Patents on Anti-Infective Drug Discovery Vaccines for Cytomegalovirus
Infectious Disorders - Drug Targets T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Mechanisms of Cell Signaling and Inflammation in Alzheimers Disease
Current Drug Targets - Inflammation & Allergy Current Experimental Therapy for Alzheimers Disease
Current Neuropharmacology Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Autophagy: For Better or for Worse, in Good Times or in Bad Times …
Current Molecular Medicine Sudden Infant Death Following Hexavalent Vaccination: A Neuropathologic Study
Current Medicinal Chemistry In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents Apathy: A Conceptual Review
Current Psychiatry Research and Reviews Update on ICOS: A Possible Target for Turning-Off Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Convulsions with Gastroenteritis: Reflections on some Cases and Tentative Diagnostic Score
Current Pediatric Reviews Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Molecules of Infectious Agents as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry